Demetrix has signed its first contract manufacturing organization, or CMO, partner for commercial scale production of rare cannabinoids using fermentation. Demetrix will add additional CMO partners in the future to meet further growth and customer needs.
Demetrix Plans to Bring CBG to Market
Demetrix’s first CMO partner is an FDA-registered, food cGMP-compliant facility. Through the CMO, Demetrix will be able to produce metric tons of rare cannabinoids annually, delivering a steady, sustainable stream of safe, high-purity, affordable ingredients for consumer product companies. The first ingredient Demetrix plans to bring to market is the rare cannabinoid cannabigerol, or CBG.
Through its proven mastery of bioprocesses, cutting-edge equipment and stringent quality and safety standards, this CMO will be able to rapidly integrate Demetrix’s highly specialized technology to produce metric tons of ingredients annually. The partnership intends to deliver rare cannabinoids at attractive price points with the sustainability, safety and purity metrics demanded by the world’s largest consumer products companies.
“
After several successful demo scale production runs, Demetrix is extending its leadership position in the industry by partnering with a commercial scale CMO to deliver cannabinoids to consumer product companies at a global scale. We are on track to commercialize our business later this year,” commeneted Jeff Ubersax, chief executive officer, Demetrix.
Source: Demetrix